BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35346092)

  • 1. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Done N; Petigara T; Mohanty S; Song Y; Liu Q; Lemus-Wirtz E; Signorovitch J; Sarpong E; Weiss T
    BMC Infect Dis; 2022 Mar; 22(1):294. PubMed ID: 35346092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England.
    Mohanty S; Podmore B; Cuñado Moral A; Weiss T; Matthews I; Sarpong E; Méndez I; Qizilbash N
    BMC Public Health; 2023 Jan; 23(1):201. PubMed ID: 36717794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis.
    Hu T; Sarpong EM; Song Y; Done N; Liu Q; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    Pneumonia (Nathan); 2023 Apr; 15(1):8. PubMed ID: 37016411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018.
    Hu T; Song Y; Done N; Mohanty S; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Weiss T
    BMC Health Serv Res; 2023 Apr; 23(1):398. PubMed ID: 37098521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019.
    Mohanty S; Done N; Liu Q; Song Y; Wang T; Gaburo K; Sarpong EM; White M; Weaver JP; Signorovitch J; Weiss T
    Vaccine; 2024 Apr; 42(11):2758-2769. PubMed ID: 38485640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008-2019).
    Macaj M; Perdochova L; Jakubikova J
    Vaccine; 2023 Jan; 41(2):452-459. PubMed ID: 36470684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal conjugate vaccines for preventing otitis media.
    Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2014 Apr; (4):CD001480. PubMed ID: 24696098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of acute otitis media, recurrent otitis media and tympanostomy tube insertion in children after its implementation into the national immunization program in Turkey.
    Soysal A; Gönüllü E; Yıldız I; Aydemir G; Tunç T; Fırat Y; Erdamar B; Karaböcüoğlu M
    Hum Vaccin Immunother; 2020; 16(2):445-451. PubMed ID: 31424317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Otitis Media Episodes and Pressure Equalization Tube Insertions Among Young Children Following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine: A Birth Cohort-based Study.
    Wiese AD; Huang X; Yu C; Mitchel EF; Kyaw MH; Griffin MR; Grijalva CG
    Clin Infect Dis; 2019 Nov; 69(12):2162-2169. PubMed ID: 30770533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: Incidence, serotype distribution and vaccine's effectiveness.
    Ochoa-Gondar O; Figuerola-Massana E; Vila-Corcoles A; Aguirre CA; de Diego C; Satue E; Gomez F; Raga X;
    Int J Pediatr Otorhinolaryngol; 2015 Dec; 79(12):2104-8. PubMed ID: 26453272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of pneumococcal conjugate vaccines on acute otitis media in Japan.
    Sasaki A; Kunimoto M; Takeno S; Sumiya T; Ishino T; Sugino H; Hirakawa K
    Auris Nasus Larynx; 2018 Aug; 45(4):718-721. PubMed ID: 29102419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine.
    Casey JR; Adlowitz DG; Pichichero ME
    Pediatr Infect Dis J; 2010 Apr; 29(4):304-9. PubMed ID: 19935445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom.
    Lau WC; Murray M; El-Turki A; Saxena S; Ladhani S; Long P; Sharland M; Wong IC; Hsia Y
    Vaccine; 2015 Sep; 33(39):5072-9. PubMed ID: 26297875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.